Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bronchodilator is a therapeutic class of drugs, not a molecular target or receptor itself. It describes any drug that causes the airways to widen, making breathing easier. This effect is achieved by various drugs acting on multiple distinct molecular targets, such as beta-2 adrenergic receptors, muscarinic acetylcholine receptors, and phosphodiesterase enzymes. Therefore, 'Bronchodilator' is a functional/pharmacological classification rather than a specific molecular entity targeted by drugs.
Bronchodilators achieve their effect of airway dilation by acting on various distinct molecular targets, including beta-2 adrenergic receptors, muscarinic acetylcholine receptors (primarily M3), and phosphodiesterase enzymes. Their common mechanism is to relax the smooth muscles surrounding the airways, thereby increasing airflow.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bronchodilator (Therapeutic Class) (N/A).